The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Months after filing for bankruptcy, VBI Vaccines is taking the next step in shuttering operations with the voluntarily ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

The people piece of pharma’s digital transformation remains a problem. That is the top takeaway from a GlobalData survey, ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

After pledging to allow politician and vaccine skeptic Robert Francis Kennedy Jr. | Trump's appointment follows his ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...